Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients.

Breast · 2021 · PMC8321956 · PMID 34298300

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We included the interaction term, “drug difference of anti-HER2 antibody × log(HR) of PFS,” as a covariate in the mixed-effects linear meta-regression analysis of HR for OS, but it did not reach statistical significance in the final mixed-effects linear meta-regression model.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.